Largest Indicative Borrow Rate Increases: Humacyte 16.96%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 15 2026
0mins
Latest data shows the largest indicative borrow rate increases among liquid option names include: Humacyte (HUMA) 16.96% +1.30, Infosys (INFY) 14.10% +1.29, Defiance 1.75x MSTR ETF (MSTX) 27.68% +1.03, Yellowstone Midco Holdings Ii, Llc (YSS) 5.98% +0.78, Mesoblast (MESO) 9.20% +0.53, Navient (NAVI) 0.94% +0.53, Equinor (EQNR) 1.81% +0.51, Rumble (RUM) 7.11% +0.49, Lucid Group (LCID) 27.88% +0.35, and Palladyne AI Corp (PDYN) 16.25% +0.33.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HUMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HUMA
Wall Street analysts forecast HUMA stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.070
Low
3.00
Averages
5.88
High
11.00
Current: 1.070
Low
3.00
Averages
5.88
High
11.00
About HUMA
Humacyte, Inc. is a commercial-stage biotechnology platform company. The Company is engaged in developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a range of diseases, injuries, and chronic conditions. It is using its proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels (ATEVs). The Company is also in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The Company is also engaged in the preclinical development of coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple cell and tissue applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biotech Sector Sees Surge in FDA and Global Approvals
- FDA Approval Boosts Innovation: Guardant Health (GH) secured FDA approval for its Guardant360 CDx liquid biopsy test as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS, highlighting the growing importance of liquid biopsy in advanced cancer treatment, which is expected to drive GH's market share growth.
- Therapy Expansion: Eli Lilly (LLY) received FDA approval for an every-eight-week maintenance dose of EBGLYSS, with Q1 2026 sales surging 141% to $145 million, reflecting strong demand in its immunology portfolio and further solidifying the company's market position.
- China Market Breakthrough: Vor Bio (VOR) announced that Telitacicept received approval from China's NMPA, becoming the only approved therapy for Sjögren's disease in the country, supported by positive Phase 3 trial data, which is expected to significantly improve patient quality of life and expand market reach.
- EU Approval for New Therapy: Sanofi (SNY) secured European Commission approval for Sarclisa in newly diagnosed multiple myeloma patients, based on Phase 3 IRAKLIA trial results, which is expected to enhance Sarclisa's application range and strengthen the company's competitiveness in blood cancer treatment.
See More
Humacyte Prices Public Offering to Raise $50M
- Offering Size: Humacyte announced a public offering of 47.62 million shares at $1.05 per share, aiming to raise approximately $50 million, reflecting the company's proactive financing strategy in the capital markets.
- Underwriter Selection: The offering is managed by Barclays, BTIG, and Titan Partners, indicating that the company has chosen strong financial institutions to support its fundraising efforts, thereby enhancing market confidence.
- Use of Proceeds: Humacyte intends to utilize the net proceeds for the commercialization of its Human Acellular Vessel platform, Symvess®, advance its Biologics License Application for hemodialysis, and accelerate product pipeline development, showcasing the company's strategic focus on future growth.
- Additional Share Option: The underwriters have the option to purchase an additional 7.14 million shares within 30 days at the same price, further enhancing the offering's flexibility and potential funding capacity, ensuring the company's financial stability amid market fluctuations.
See More
Stock Futures Rebound as Navan Reports Strong Earnings
- Navan Earnings Beat: Navan reported a non-GAAP EPS of $0.08 for Q1, exceeding estimates by $0.07, with revenue of $220.3 million surpassing consensus by $15 million, and raised its FY2027 revenue guidance to $907 million-$913 million, indicating a robust market performance and improved profitability with approximately 30% year-over-year growth.
- Humacyte Financing Pressure: Humacyte priced an underwritten public offering of 47.6 million shares at $1.05 each, raising about $50 million, but the stock fell 16%, reflecting market concerns about its growth potential amid fierce competition in the biotechnology sector.
- PureCycle Capital Raise: PureCycle Technologies announced concurrent capital raises totaling roughly $395 million, including $250 million of convertible senior notes and an equity offering of 17.7 million shares, with expected net proceeds of approximately $379 million, yet the stock tumbled 14%, indicating market caution regarding its financing strategy.
- Oracle Earnings Reaction: Despite Oracle's Q4 revenue rising 21% year-over-year to $19.2 billion and adjusted EPS of $2.11 beating expectations, the stock dropped 10% due to investor concerns over aggressive capital needs and declining trends in legacy software, reflecting market wariness about its future AI investments.
See More
Humacyte Reports Positive Interim Results for ATEV in Phase 3 Study
- Clinical Trial Success: Humacyte's Phase 3 V012 study demonstrates that female dialysis patients receiving ATEV implants achieved an average of 220 catheter-free days, significantly surpassing the 129 days for autologous AV fistula patients, indicating ATEV's effectiveness in dialysis access.
- Safety Advantage: In terms of primary safety measures, ATEV patients experienced an infection rate of 6 per 100 patient-years, markedly lower than the 23 per 100 patient-years for AV fistula patients, with no access-related infections reported among ATEV patients, highlighting its clinical safety.
- Public Offering Plan: Humacyte concurrently announced a public offering of 47.62 million shares at $1.05 per share, expecting to raise $50 million, with proceeds aimed at funding the commercialization of Symvess and supplementing its Biologics License Application, thereby strengthening its financial position.
- Significant Market Potential: Humacyte estimates over 800,000 Americans suffer from end-stage kidney disease, with nearly 500,000 relying on dialysis; the introduction of ATEV is expected to address the failure rates of autologous AV fistulas in women, thereby expanding market share.
See More
Humacyte Prices Public Offering at $1.05 per Share
- Offering Size: Humacyte has announced a public offering of 47,619,048 shares at a price of $1.05 per share, with expected gross proceeds of $50 million, indicating the company's active engagement in capital markets and its ability to raise funds.
- Use of Proceeds: The net proceeds from this offering will be utilized for the commercialization of Symvess®, filing a Biologics License Application supplement for a hemodialysis indication, and related activities, demonstrating the company's strategic commitment to product development and market expansion.
- Underwriter Selection: Barclays, BTIG, and Titan Partners are acting as joint book-running managers for the offering, showcasing the company's professionalism and market credibility in selecting partners.
- Registration Statement Validity: The S-3 registration statement filed with the SEC in September 2025 has been declared effective, ensuring compliance and smooth execution of the offering, reflecting the company's diligence in regulatory adherence.
See More
Humacyte Initiates Underwritten Public Offering
- Public Offering Launch: Humacyte has announced the commencement of its underwritten public offering of common stock, indicating the company's need for financing and confidence in the biotechnology sector under favorable market conditions.
- Underwriter Option: The company plans to grant underwriters an option to purchase up to an additional 15% of shares within 30 days, a strategy aimed at maximizing fundraising potential and enhancing demand for its stock in the market.
- Clear Use of Proceeds: Humacyte intends to use the net proceeds from the offering to fund the commercialization of Symvess®, the filing of a Biologics License Application supplement, and the development of product candidates, demonstrating the company's proactive approach to future growth.
- Registration Statement Approved: The S-3 registration statement filed with the SEC in September 2025 has been declared effective, ensuring compliance and transparency for the offering, which is expected to bolster investor confidence.
See More
Biotech Sector Sees Surge in FDA and Global Approvals
- FDA Approval Boosts Innovation: Guardant Health (GH) secured FDA approval for its Guardant360 CDx liquid biopsy test as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS, highlighting the growing importance of liquid biopsy in advanced cancer treatment, which is expected to drive GH's market share growth.
- Therapy Expansion: Eli Lilly (LLY) received FDA approval for an every-eight-week maintenance dose of EBGLYSS, with Q1 2026 sales surging 141% to $145 million, reflecting strong demand in its immunology portfolio and further solidifying the company's market position.
- China Market Breakthrough: Vor Bio (VOR) announced that Telitacicept received approval from China's NMPA, becoming the only approved therapy for Sjögren's disease in the country, supported by positive Phase 3 trial data, which is expected to significantly improve patient quality of life and expand market reach.
- EU Approval for New Therapy: Sanofi (SNY) secured European Commission approval for Sarclisa in newly diagnosed multiple myeloma patients, based on Phase 3 IRAKLIA trial results, which is expected to enhance Sarclisa's application range and strengthen the company's competitiveness in blood cancer treatment.
See More
Humacyte Prices Public Offering to Raise $50M
- Offering Size: Humacyte announced a public offering of 47.62 million shares at $1.05 per share, aiming to raise approximately $50 million, reflecting the company's proactive financing strategy in the capital markets.
- Underwriter Selection: The offering is managed by Barclays, BTIG, and Titan Partners, indicating that the company has chosen strong financial institutions to support its fundraising efforts, thereby enhancing market confidence.
- Use of Proceeds: Humacyte intends to utilize the net proceeds for the commercialization of its Human Acellular Vessel platform, Symvess®, advance its Biologics License Application for hemodialysis, and accelerate product pipeline development, showcasing the company's strategic focus on future growth.
- Additional Share Option: The underwriters have the option to purchase an additional 7.14 million shares within 30 days at the same price, further enhancing the offering's flexibility and potential funding capacity, ensuring the company's financial stability amid market fluctuations.
See More
Stock Futures Rebound as Navan Reports Strong Earnings
- Navan Earnings Beat: Navan reported a non-GAAP EPS of $0.08 for Q1, exceeding estimates by $0.07, with revenue of $220.3 million surpassing consensus by $15 million, and raised its FY2027 revenue guidance to $907 million-$913 million, indicating a robust market performance and improved profitability with approximately 30% year-over-year growth.
- Humacyte Financing Pressure: Humacyte priced an underwritten public offering of 47.6 million shares at $1.05 each, raising about $50 million, but the stock fell 16%, reflecting market concerns about its growth potential amid fierce competition in the biotechnology sector.
- PureCycle Capital Raise: PureCycle Technologies announced concurrent capital raises totaling roughly $395 million, including $250 million of convertible senior notes and an equity offering of 17.7 million shares, with expected net proceeds of approximately $379 million, yet the stock tumbled 14%, indicating market caution regarding its financing strategy.
- Oracle Earnings Reaction: Despite Oracle's Q4 revenue rising 21% year-over-year to $19.2 billion and adjusted EPS of $2.11 beating expectations, the stock dropped 10% due to investor concerns over aggressive capital needs and declining trends in legacy software, reflecting market wariness about its future AI investments.
See More
Humacyte Reports Positive Interim Results for ATEV in Phase 3 Study
- Clinical Trial Success: Humacyte's Phase 3 V012 study demonstrates that female dialysis patients receiving ATEV implants achieved an average of 220 catheter-free days, significantly surpassing the 129 days for autologous AV fistula patients, indicating ATEV's effectiveness in dialysis access.
- Safety Advantage: In terms of primary safety measures, ATEV patients experienced an infection rate of 6 per 100 patient-years, markedly lower than the 23 per 100 patient-years for AV fistula patients, with no access-related infections reported among ATEV patients, highlighting its clinical safety.
- Public Offering Plan: Humacyte concurrently announced a public offering of 47.62 million shares at $1.05 per share, expecting to raise $50 million, with proceeds aimed at funding the commercialization of Symvess and supplementing its Biologics License Application, thereby strengthening its financial position.
- Significant Market Potential: Humacyte estimates over 800,000 Americans suffer from end-stage kidney disease, with nearly 500,000 relying on dialysis; the introduction of ATEV is expected to address the failure rates of autologous AV fistulas in women, thereby expanding market share.
See More
Humacyte Prices Public Offering at $1.05 per Share
- Offering Size: Humacyte has announced a public offering of 47,619,048 shares at a price of $1.05 per share, with expected gross proceeds of $50 million, indicating the company's active engagement in capital markets and its ability to raise funds.
- Use of Proceeds: The net proceeds from this offering will be utilized for the commercialization of Symvess®, filing a Biologics License Application supplement for a hemodialysis indication, and related activities, demonstrating the company's strategic commitment to product development and market expansion.
- Underwriter Selection: Barclays, BTIG, and Titan Partners are acting as joint book-running managers for the offering, showcasing the company's professionalism and market credibility in selecting partners.
- Registration Statement Validity: The S-3 registration statement filed with the SEC in September 2025 has been declared effective, ensuring compliance and smooth execution of the offering, reflecting the company's diligence in regulatory adherence.
See More
Humacyte Initiates Underwritten Public Offering
- Public Offering Launch: Humacyte has announced the commencement of its underwritten public offering of common stock, indicating the company's need for financing and confidence in the biotechnology sector under favorable market conditions.
- Underwriter Option: The company plans to grant underwriters an option to purchase up to an additional 15% of shares within 30 days, a strategy aimed at maximizing fundraising potential and enhancing demand for its stock in the market.
- Clear Use of Proceeds: Humacyte intends to use the net proceeds from the offering to fund the commercialization of Symvess®, the filing of a Biologics License Application supplement, and the development of product candidates, demonstrating the company's proactive approach to future growth.
- Registration Statement Approved: The S-3 registration statement filed with the SEC in September 2025 has been declared effective, ensuring compliance and transparency for the offering, which is expected to bolster investor confidence.
See More
